增强的Everolimus输送:开发和评估一个纳米悬浮配方
Qiao Zeng1, Jie Chen1, Han Zhang1
1School of Pharmacy, Hangzhou Medical College, Hangzhou, Zhejiang, People's Republic of China.
International journal of nanomedicine
|January 7, 2026
概括
含有Everolimus的纳米悬浮剂通过减少血管生长和炎症,有效地治疗角膜新血管化 (CNV). 这种配方显示出对眼部输送的承诺,具有良好的生物相容性和最小的刺激.
科学领域:
- 眼科医生 眼科 眼科
- 纳米技术 纳米技术
- 药理学 药理学是指药理学的学科.
背景情况:
- 角膜新血管化 (CNV) 是一种病理过程,其特点是角膜中的血管异常生长.
- CNV可能导致视力受损,并与炎症和血管生成有关.
- 目前对中枢神经炎的治疗可能存在局限性,需要开发新的治疗策略.
研究的目的:
- 开发和描述用于治疗角膜新血管化 (CNV) 的Everolimus装载纳米悬浮剂 (EV-sus).
- 评估EV-sus的细胞吸收在体外,抗血管原效应,以及体内疗效在CNV模型中.
- 评估EV-sus配方用于眼部的安全性和耐受性.
主要方法:
- 使用溶剂挥发技术,Everolimus被封装成纳米悬浮剂.
- 描述包括药物度,颗粒大小和泽塔电位测量.
- 试验室研究包括评估角膜上皮细胞的细胞吸收和对内皮细胞的抗血管原作用.
- 在体内,用RT-qPCR分析新血管化和炎症标志物,在子CNV模型中评估了疗效.
- 通过子眼部刺激测试来评估眼部安全性.
主要成果:
- 开发的EV-sus的药物度为0.96 mg·mL-1,颗粒大小为141.0 ± 1.0 nm,泽塔电位为-12.2 ± 0.4 mV.
- 通过多个内细胞通路,EV-sus证明了依赖时间和能量的细胞吸收.
- 这些纳米悬浮物有效地抑制了HUVEC中VEGF诱导的增殖,迁移和管形成.
- 在体内,EV-sus显著减少了新血管化,血管长度和CNV模型中的面积.
- 炎症标志物 (IL-1,IL-6,VEGF,TNF-α) 和MMP-9的表达因EV-sus治疗而减少.
- 在子眼部刺激测试中,该配方被发现是安全的,并且耐受性很好.
结论:
- 载有Everolimus的纳米悬浮剂 (EV-sus) 是用于角膜新血管化的有前途的治疗方法.
- 该配方表现出高效的细胞吸收,强大的抗血管性活性和良好的生物相容性.
- EV-sus适用于眼部施用,并有可能在最小的眼部刺激下减轻中枢神经病毒的进展.
相关概念视频
01:23Factors Affecting Dissolution: Particle Size and Effective Surface Area
1.6K
Dissolution kinetics, an essential aspect of oral drug delivery, is significantly influenced by the drug's particle size. According to the Noyes-Whitney dissolution model, the dissolution rate correlates directly with the drug's surface area. The larger the surface area, the higher the drug's solubility in water, leading to a faster drug dissolution rate. Reducing particle size increases the effective surface area, enhancing the dissolution process. Micronization and nanosizing are...
1.6K
01:16Bioavailability Enhancement: Drug Solubility Enhancement
212
Body:Bioavailability is a critical factor in determining a drug's effectiveness. It refers to the proportion of a drug that enters the circulation when introduced into the body and is, as a result, able to have an active effect. Enhancing bioavailability is essential for drugs with poor solubility, as it can significantly impact their therapeutic efficacy. Various methods are employed to increase the solubility of drugs, thereby enhancing their bioavailability.Micronization and nanonization are...
212
01:05Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
193
Body:Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
193
01:27Bioavailability Enhancement: Drug Permeability Enhancement
183
Body:After oral administration, poor permeability often limits the rate at which drugs are absorbed through the intestinal epithelium. Enhancing drug permeability is crucial for effective therapy, and several strategies have been developed to overcome this challenge.One effective strategy involves the use of lipid-based formulations. These formulations enhance dissolution and solubility, targeting physiological mechanisms to increase drug absorption. This includes stimulating bile salt...
183
01:28Factors Influencing Drug Absorption: Pharmaceutical Parameters
392
Solid dosage forms such as tablets and capsules undergo rigorous manufacturing processes to ensure stability and effectiveness. Their dissolution and absorption properties are influenced significantly by the choice of excipients (inactive ingredients that serve various roles in the formulation), and the methodology applied during production. The manufacturing parameters, such as compression force and granulation techniques, significantly affect dissolution rates. Elevated compression forces...
392